MedTrace Logo

Prospective Evaluation of AI R&D Tool for Patient Stratification: a Trial for Renal Immuno-oncology Model Experimental Evaluation 2

NCT06264479 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 7

Last updated 2025-07-30

No results posted yet for this study

Summary

Pear Bio has developed a predictive biomarker technology that combines 3D cell culture, microscopy and computer vision to measure the response of an individual patient's tumor sample to different systemic therapy regimens that are tested simultaneously ex vivo.

This study will recruit patients with advanced or metastatic kidney cancer who are due to start a clinically-indicated new line of therapy.

The oncologist will be blinded to the response on the Pear Bio test (the test will be run in parallel with the patient's treatment). The primary objective of this study is to establish the sensitivity and specificity of Pear Bio's test results against patient outcomes (objective response, progression-free survival, depth and duration of response, overall survival).

Conditions

Interventions

PROCEDURE

Biopsy

Patients undergo a biopsy from a lesion, and give 40ml of blood

Sponsors & Collaborators

  • Royal Free Hospital NHS Foundation Trust

    collaborator OTHER

  • Cambridge University Hospitals NHS Trust

    collaborator UNKNOWN

  • East & North Herts NHS Trust

    collaborator UNKNOWN

  • Imperial College Healthcare NHS Trust

    collaborator OTHER

  • Ourotech, Inc.

    lead INDUSTRY

Principal Investigators

  • Ekaterini Boleti · Royal Free Hospital NHS Foundation Trust

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-19
Primary Completion
2025-07-25
Completion
2025-07-25

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06264479 on ClinicalTrials.gov